Pharmacokinetic considerations and dosing strategies of antibiotics in the critically ill patient

Journal of the Intensive Care Society

Volumn 16, Issue 2, 2015, Pages 147-153

  Shah, Snehal ^a   Barton, Greg ^b   Fischer, Andreas ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b WHISTON HOSPITAL   (United Kingdom)

Author keywords

Antibiotics; Beta lactams; Critical care; Pharmacokinetics; Sepsis

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAM ANTIBIOTIC; GLYCOPEPTIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; CRITICALLY ILL PATIENT; DRUG CLEARANCE; DRUG DOSE; ELIMINATION HALF-LIFE; HYDROPHILICITY; LIPOPHILICITY; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MINIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PROTEIN BINDING; RENAL CLEARANCE; SEPSIS; VOLUME OF DISTRIBUTION;

EID: 84945184672     PISSN: 17511437     EISSN: None     Source Type: Journal    
DOI: 10.1177/1751143714564816     Document Type: Article

References (29)

1. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302: 2323–2329.
2. Rice T, and Bernard G. Therapeutic intervention and targets for sepsis. Annu Rev Med 2005; 56: 225–248.
3. Roberts J, Paul S, Akova M, et al. DALI: defining antibiotic levels in intensive care patients: are current b-lactam antibiotic doses sufficient for critically ill patients. Clin Inf Dis 2014; 58: 1072–1083.
4. Roberts J, Kruger P, Paterson D, et al. Antibiotic resistance–what’s dosing got to do with it? Crit Care Med 2008; 36: 2433–2440.
5. Peleg A, Potoski B, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007; 59: 128–131.
6. Roberts J, and Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37: 840–851.
7. Sun H, Frassetto L, and Benet L. Effects of renal failure on drug transport and metabolism. Pharmacol Ther 2006; 109: 1–11.
8. Finfer S, Bellomo R, and Boyce N. A comparison of albumin and saline for fluid resuscitation in the intensive care unit, the SAFE study investigators. N Engl J Med 2004; 350: 2247–2256.
9. Ulldemolins M, Roberts JA, Wallis SC, et al. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. J Antimicrob Chemother 2010; 65: 1771–1778.
10. Burkhardt O, Kumar V, Katterwe D, et al. Ertapenem in critically ill patients with early-onsetventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother 2007; 59: 277–284.
11. Barbot A, Venisse N, Rayeh F, et al. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors. Intensive Care Med 2003; 29: 1528–1534.
12. Panidis D, Markantonis SL, Boutzouka E, et al. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest 2005; 128: 545–552.
13. EUCAST. Aminoglycosides: EUCAST clinical MIC breakpoints, http://www.eucast.org/clinical_breakpoints/ (accessed 21 July 2014).
14. Roberts J, and Lipman J. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med 2013; 41: 489–459.
15. Muzevich K, and Lee K. Subtherapeutic linezolid concentrations in a patient with morbid obesity and methicillin-resistant Staphylococcus aureus pneumonia: case report and review of the literature. Ann Pharmacother 2013; 47: e25.
16. Erstad B. Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Med 2004; 30: 18–32.
17. Udy AA, Varghese JM, Altukroni M, et al. Subtherapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012; 142: 30–39.
18. Waele J, Carrette S, Carlier M, et al. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med 2014; 40: 380–387.
19. Moore RD, Lietman P, and Smith C. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infec Dis 1987; 155: 93–99.
20. Deziel-Evans LM, Murphy JE, and Job ML. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm 1986; 5: 319–324.
21. Pinder M, Bellomo R, and Lipman J. Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care 2002; 30: 134–144.
22. Taccone F, Laterre P, Spapen H, et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 2010; 14: R53.
23. McKinnon P, Paladino J, and Schentag J. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T >MIC) as predictors of outcomes for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008; 31: 345–351.
24. Lorente L, Jimenez A, Martin MM, et al. Clinical cure of ventilator associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009; 33: 464–468.
25. Lorente L, Lorenzo L, Martin MM, et al. Meropenem by continuous versus intermittent infusion in ventilator associated pneumonia due to gram negative bacilli. Ann Pharmacother 2006; 40: 219–223.
26. Lorente L, Jimenez A, Palmero S, et al. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open label, historical chart review. Clin Ther 2007; 29: 2433–2439.
27. Chant C, Leung A, and Friedrich J. Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta-analysis. Critical Care 2013; 17: R279.
28. Van Zanten A, Polder-Man K, Van Geijlswijk I, et al. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care 2008; 23: 422–430.
29. Llopis-Salvia P, and Jimenez-Torres N. Population pharmacokinetics parameters of vancomycin in critically ill patients. J Clin Pharm Ther 2006; 31: 447–454.